Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Verheyen, N; Grübler, MR; Meinitzer, A; Trummer, C; Schwetz, V; Amrein, K; Dimai, HP; März, W; Catena, C; von Lewinski, D; Voelkl, J; Alesutan, I; Fahrleitner-Pammer, A; Brussee, H; Pilz, S; Tomaschitz, A.
Effect of eplerenone on markers of bone turnover in patients with primary hyperparathyroidism - The randomized, placebo-controlled EPATH trial.
Bone. 2017; 105(5):212-217
Doi: 10.1016/j.bone.2017.08.030
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Verheyen Nicolas Dominik
- Co-Autor*innen der Med Uni Graz
- Amrein Karin
- Brussee Helmut
- Dimai Hans Peter
- Fahrleitner-Pammer Astrid
- Grübler Martin
- März Winfried
- Meinitzer Andreas
- Pilz Stefan
- Theiler-Schwetz Verena
- Tomaschitz Andreas
- Trummer Christian
- von Lewinski Dirk
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Mineralocorticoid receptor (MR) antagonism may affect bone turnover via direct and indirect pathways involving parathyroid hormone, but randomized controlled trials are lacking. In a pre-specified analysis of the "Eplerenone in primary hyperparathyroidism" placebo-controlled, randomized trial (ISRCTN 33941607), effects of eight weeks MR-blockade with eplerenone on bone turnover markers in 97 patients with primary hyperparathyroidism were tested. Mean age was 67.5±9.5years, and 76 (78.4%) were females. In analysis of covariance with adjustment for baseline values, eplerenone had no significant effect on isoform 5b of the tartrate-resistant acid phosphatase (TRAP), beta-crosslaps, N-terminal propeptide of procollagen type 1 (P1NP), osteocalcin and bone-specific alkaline phosphatase. There was no significant cross-sectional correlation between plasma aldosterone concentration or the aldosterone-to-renin ratio and markers of bone turnover in multivariate linear regression models at baseline. These data provide first evidence from a randomized and placebo-controlled trial that short-term MR antagonism may not affect bone turnover, at least in patients with primary hyperparathyroidism. Copyright © 2017 Elsevier Inc. All rights reserved.
- Find related publications in this database (using NLM MeSH Indexing)
- Aged -
- Biomarkers - metabolism
- Bone Remodeling - drug effects
- Cohort Studies -
- Female -
- Follow-Up Studies -
- Humans -
- Hyperparathyroidism, Primary - drug therapy
- Hyperparathyroidism, Primary - metabolism
- Male -
- Placebos -
- Renin-Angiotensin System -
- Spironolactone - analogs & derivatives
- Spironolactone - pharmacology
- Spironolactone - therapeutic use
- Treatment Outcome -
- Find related publications in this database (Keywords)
- Bone turnover
- Mineralocorticoid receptor
- Eplerenone
- Primary hyperparathyroidism
- Randomized controlled trial